Physician profile
Anan Haija
NPI 1487869152
$196,352.95
in general payments reported to CMS, 2019-2025
33 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $27K · 2021: $18K · 2022: $39K · 2023: $37K · 2024: $21K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Food and Beverage: $9,840 · Travel and Lodging: $1,658 · Education: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,238.25 |
| Food and Beverage | $9,840.03 |
| Travel and Lodging | $1,658.23 |
| Education | $387.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $118,583.23 | 2019-2025 | |
| Amgen INC. | $28,964.44 | 2019-2025 | Otezla, Tavneos, Evenity |
| Novartis Pharmaceuticals Corporation | $18,029.97 | 2019-2025 | |
| Celgene Corporation | $13,806.86 | 2019 | |
| Aurinia Pharma U.S., INC. | $7,108.43 | 2021-2025 | Lupkynis |
| Janssen Biotech, INC. | $2,170.49 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharma Ag | $1,425.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $976.51 | 2021-2025 | Saphnelo, Evusheld |
| Ucb, INC. | $890.29 | 2020-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $887.12 | 2020-2025 | Benlysta |
| Horizon Therapeutics Plc | $655.79 | 2020-2023 | Krystexxa, Uplizna |
| Ani Pharmaceuticals, INC. | $570.96 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $539.79 | 2020-2025 | Acthar |
| Lilly USA, LLC | $486.88 | 2021-2024 | Taltz, Olumiant |
| Genzyme Corporation | $297.41 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $225.93 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $132.46 | 2023-2025 | Strensiq |
| Genentech USA, INC. | $111.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $78.03 | 2020-2025 | Orencia |
| Zimmer Biomet Holdings, INC. | $52.46 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Organon LLC | $49.82 | 2023-2025 | Renflexis, Hadlima |
| Radius Health, INC. | $33.65 | 2025 | Tymlos |
| Fresenius Kabi USA, LLC | $31.55 | 2024 | Idacio |
| Kyowa Kirin, INC. | $31.15 | 2025 | |
| Fidia Pharma USA INC. | $23.99 | 2024 | Hyalgan |
| Tonix Medicines, INC. | $17.90 | 2025 | Tonmya |
| Novo Nordisk INC | $15.88 | 2025 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $15.51 | 2023 | Seglentis |
| Amag Pharmaceuticals, INC. | $14.97 | 2021 | |
| Avion Pharmaceuticals | $14.74 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $14.00 | 2023 | Arcalyst |
| Sandoz INC. | $13.97 | 2025 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anan Haija listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.